Chuang Hao-Yuan 4

What Happened
Chuang Hao-Yuan, Chief Financial Officer of Belite Bio, had 144,868 ordinary shares vest on March 31, 2026 under a previously granted option award. The Form 4 reports the acquisition as a derivative award (transaction code A) with an acquisition price of $0.00; no concurrent sale was reported.

Key Details

• Transaction date: 2026-03-31 (Form 4 filed 2026-04-02). Filing appears timely (within the Form 4 two-business-day window).
• Security/amount: 144,868 ordinary shares vested and were acquired (derivative). Reported price: $0.00.
• Post-transaction beneficial ownership: Not specified in the provided excerpt of the filing.
• Footnote: The option was granted on December 23, 2020 and vests upon satisfaction of performance criteria. 144,868 shares had previously vested and remained exercisable; meeting one performance criterion on 3/31/2026 caused an additional 144,868 shares to vest.
• Transaction type: Vesting of option/award (derivative acquisition), not an open-market purchase or sale.

Context
This is a vesting of previously granted equity tied to performance — effectively an insider acquiring shares through an award rather than buying on the open market. No sale or cashless exercise was reported here, and the filing does not indicate any immediate disposition of the vested shares.